Abbott Laboratories (ABT) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Abbott Laboratories

NYSE•Healthcare•Medical Devices

$102.23-0.13(<0.01%)Pre-market

Market Cap

$178.90B

P/E

33.0x

P/S

3.8x

P/B

3.5x

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

How this company scores

GoodMetricSide Score: 65/100

Strongest: Cash & Earnings Quality (25/25); weakest: Balance Sheet & Red Flags (11/25).

Profitability17/25

Growth12/25

Balance Sheet & Red Flags11/25

Cash & Earnings Quality25/25

Strengths

Rising free cash flowStrong marginsCash-backed earningsConsistent free cash flow

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 33.0x5y range 14.6x – 36.3x

Currently near its 20-quarter median.

P/S · 3.8x5y range 3.8x – 5.8x

Currently near its 20-quarter median.

P/B · 3.5x5y range 3.4x – 7.0x

Currently below its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

Some Concerns

Margin Pressure

Watch

Operating margins declined 9.2% — watch for continued compression, which may signal competitive or cost pressure.

Leverage Risk

Watch

Debt-to-equity has risen 126.5% recently — increasing financial risk even if the current ratio is manageable.

Price & Volume

Market Cap $178.90B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $46.59B
Q. Revenue: $12.59B
TTM EBITDA: $9.27B
TTM Op. Income: $7.35B
Q. Op. Income: $1.69B
TTM Net Income: $5.42B
Q. Net Income: $928.00M
EPS: $0.53
Shares Out.: $1.74B

$46.59B in TTM revenue grew 8.1% YoY, reaching $12.59B last quarter. TTM EBITDA of $9.27B and TTM operating income of $7.35B show growth is flowing through to the bottom line. TTM net income of $5.42B means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 57.7%
EBITDA Margin: 18.7%
Op. Margin: 13.4%
Net Margin: 7.4%

Op. margin of 13.4% is down 5.0% YoY — costs are rising relative to revenue. Net margin at 7.4% and gross margin of 57.7% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 27% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 33.0x
P/S Ratio: 3.8x
P/B Ratio: 3.5x

At 33.0x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 3.8x and P/B of 3.5x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is up 94% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $109.22B
Cash: $5.10B
Long-Term Debt: $29.60B
Book Value: $51.11B
D/E Ratio: 0.6
Debt/EBITDA: 12.6

With $109.22B in assets and $29.60B in long-term debt, D/E is 0.6and book value is $51.11B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has risen for 2 consecutive quarters — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $2.49B
TTM Free Cash Flow: $7.82B
FCF Margin: 16.8%
FCF / Net Income: 1.4

TTM FCF of $7.82B on $2.49B in operating cash flow. The FCF / Net Income ratio of 1.4x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 15% — an improving trend.